SI0886645T1 - New 19-nor-pregnene derivatives - Google Patents

New 19-nor-pregnene derivatives

Info

Publication number
SI0886645T1
SI0886645T1 SI9730015T SI9730015T SI0886645T1 SI 0886645 T1 SI0886645 T1 SI 0886645T1 SI 9730015 T SI9730015 T SI 9730015T SI 9730015 T SI9730015 T SI 9730015T SI 0886645 T1 SI0886645 T1 SI 0886645T1
Authority
SI
Slovenia
Prior art keywords
new
pregnene derivatives
pregnene
derivatives
Prior art date
Application number
SI9730015T
Other languages
English (en)
Slovenian (sl)
Inventor
Alain Piasco
Jean Lafay
Remi Delansorne
Jacques Paris
Jean-Claude Pascal
Original Assignee
Laboratoire Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Theramex filed Critical Laboratoire Theramex
Publication of SI0886645T1 publication Critical patent/SI0886645T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/006Ketals at position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016Oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
SI9730015T 1996-01-22 1997-01-17 New 19-nor-pregnene derivatives SI0886645T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96400146A EP0785212A1 (en) 1996-01-22 1996-01-22 New 19-nor-pregnene derivatives
EP97902235A EP0886645B1 (en) 1996-01-22 1997-01-17 New 19-nor-pregnene derivatives
PCT/EP1997/000357 WO1997027210A1 (en) 1996-01-22 1997-01-17 New 19-nor-pregnene derivatives

Publications (1)

Publication Number Publication Date
SI0886645T1 true SI0886645T1 (en) 1999-12-31

Family

ID=8225217

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730015T SI0886645T1 (en) 1996-01-22 1997-01-17 New 19-nor-pregnene derivatives

Country Status (36)

Country Link
US (1) US6180803B1 (cs)
EP (2) EP0785212A1 (cs)
JP (2) JP4368945B2 (cs)
KR (1) KR100396902B1 (cs)
CN (1) CN1187366C (cs)
AP (1) AP1176A (cs)
AR (1) AR005500A1 (cs)
AT (1) ATE184015T1 (cs)
BR (1) BR9707064A (cs)
CA (1) CA2243504C (cs)
CO (1) CO4810230A1 (cs)
CZ (1) CZ292047B6 (cs)
DE (1) DE69700470T2 (cs)
DZ (1) DZ2169A1 (cs)
EE (1) EE03692B1 (cs)
ES (1) ES2140961T3 (cs)
GR (1) GR3031954T3 (cs)
HK (1) HK1018216A1 (cs)
HU (1) HU221796B1 (cs)
ID (1) ID15840A (cs)
IL (1) IL125379A (cs)
IS (1) IS1902B (cs)
JO (1) JO1971B1 (cs)
MY (1) MY116845A (cs)
NO (1) NO309572B1 (cs)
NZ (1) NZ330954A (cs)
OA (1) OA10813A (cs)
PE (1) PE55998A1 (cs)
PL (1) PL185608B1 (cs)
RU (1) RU2166509C2 (cs)
SI (1) SI0886645T1 (cs)
TN (1) TNSN97015A1 (cs)
TR (1) TR199801399T2 (cs)
TW (1) TW411345B (cs)
WO (1) WO1997027210A1 (cs)
ZA (1) ZA97521B (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
KR100856523B1 (ko) 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 충분한 치료효과를 보장하는 활성 화합물의 경피 및/또는경점막 투여용 신규 조성물
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
KR101285137B1 (ko) 2003-09-03 2013-07-11 미스콘 트레이딩 에스.에이. 자궁 내막증의 치료 방법
ES2377932T3 (es) 2003-10-10 2012-04-03 Ferring Bv Formulación farmacéutica transdérmica para minimizar los residuos sobre la piel
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9173915B1 (en) * 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN109364019B (zh) * 2015-09-02 2021-12-28 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593524A1 (de) * 1951-01-28 1970-08-13 Schering Ag Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden
DE1087127B (de) * 1958-12-13 1960-08-18 Schering Ag Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
FR1525916A (fr) * 1965-11-09 1968-05-24 Schering Ag Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation
US3891677A (en) * 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
US3835160A (en) * 1967-06-06 1974-09-10 Schering Corp 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby
BE757286A (fr) * 1969-10-10 1971-04-09 Ciba Geigy Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
CZ230798A3 (cs) 1998-11-11
TW411345B (en) 2000-11-11
EE9800219A (xx) 1998-12-15
WO1997027210A1 (en) 1997-07-31
PE55998A1 (es) 1998-10-01
CA2243504C (en) 2004-03-30
EP0886645A1 (en) 1998-12-30
NO983356L (no) 1998-07-21
CA2243504A1 (en) 1997-07-31
EP0886645B1 (en) 1999-09-01
HK1018216A1 (en) 1999-12-17
IL125379A0 (en) 1999-03-12
NZ330954A (en) 1998-10-28
AR005500A1 (es) 1999-06-23
IL125379A (en) 2003-05-29
BR9707064A (pt) 1999-12-28
AU1595597A (en) 1997-08-20
ES2140961T3 (es) 2000-03-01
DZ2169A1 (fr) 2002-12-25
KR100396902B1 (ko) 2004-05-03
AP1176A (en) 2003-06-30
RU2166509C2 (ru) 2001-05-10
TR199801399T2 (xx) 1998-10-21
PL327998A1 (en) 1999-01-04
EP0785212A1 (en) 1997-07-23
US6180803B1 (en) 2001-01-30
GR3031954T3 (en) 2000-03-31
JP2000503980A (ja) 2000-04-04
NO983356D0 (no) 1998-07-21
HUP9900684A3 (en) 1999-11-29
CN1209811A (zh) 1999-03-03
ID15840A (id) 1997-08-14
CO4810230A1 (es) 1999-06-30
OA10813A (en) 2003-01-28
IS4800A (is) 1998-07-21
HUP9900684A2 (hu) 1999-07-28
ATE184015T1 (de) 1999-09-15
IS1902B (is) 2003-11-20
NO309572B1 (no) 2001-02-19
KR19990081895A (ko) 1999-11-15
DE69700470T2 (de) 2000-03-30
CZ292047B6 (cs) 2003-07-16
JP4368945B2 (ja) 2009-11-18
ZA97521B (en) 1997-08-04
DE69700470D1 (de) 1999-10-07
JO1971B1 (en) 1997-12-15
AU708135B2 (en) 1999-07-29
JP2009167188A (ja) 2009-07-30
PL185608B1 (pl) 2003-06-30
HU221796B1 (hu) 2003-01-28
CN1187366C (zh) 2005-02-02
AP9801299A0 (en) 1998-09-30
EE03692B1 (et) 2002-04-15
MY116845A (en) 2004-04-30
TNSN97015A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
HU9700358D0 (en) New oxazolidinon derivatives
AP9700954A0 (en) 6-ohenylpyridyl-2-amine derivatives
HUP9900684A3 (en) New 19-nor-pregnene derivatives
AP9701156A0 (en) 6-phenylpyridyl-2-amine derivatives
IL125226A0 (en) Heterocycle-condensed morphinoid derivatives (II)
HU9700328D0 (en) New heteroaryl-oxazolidinones
EP0708091A3 (en) Indoloylguanidine derivatives
HUP9902993A3 (en) Alkylaminobenzothiazole and -benzoxazole derivatives
EP0692482A3 (en) 1-pyridyltetrazolinone derivatives
HUP9701835A3 (en) Vinyl-pirrolidinone-cephalosporin derivatives
IL129418A0 (en) 2-Methoxyphenylpiperazine derivatives
IL125149A0 (en) Pyrazol-4-yl-hetaroyl derivatives
PL334558A1 (en) Cephalosporinic derivatives
HU9701479D0 (en) N-benzylazolium derivatives
ZA972051B (en) Benzodiazonine derivatives
GB9600063D0 (en) Guaridine derivatives
GB9603226D0 (en) Heterocyclyl-ergoline derivatives
IL125974A0 (en) 2-thioxotetrahydropyrimidin-4-one derivatives
IL130283A0 (en) Polysaccharide-peptide derivatives
GB9702049D0 (en) Tetrahhydroisoquinoline derivatives
HU9800889D0 (en) New naphtylpiperazine derivatives
HU9601036D0 (en) Aryl-sulfonyl-hydroxamic-acid derivatives
GB2287463B (en) Bis-anthracycline derivatives
IL145864A0 (en) Benzothiophenecarboxamide derivatives
SG67992A1 (en) N-benzylazolium derivatives

Legal Events

Date Code Title Description
KO00 Lapse of patent

Effective date: 20121129